Pro-Gastrin-Releasing Peptide, Progrp (ProGRP) ELISA Kit for Human

Principle of the Assay: This kit was based on sandwich enzyme-linked immune-sorbent assay technology. Anti-ProGRP monoclonal antibody was pre-coated onto 96-well plates. The standards and test samples were added to the wells and any ProGRP present is bound by the immobilized antibody. After washing away any unbound substances, the HRP conjugated anti-ProGRP monoclonal antibody was added to wells as detection antibodies. Following a wash to remove any unbound antibody-enzyme reagent, the TMB substrates were added to visualize HRP enzymatic reaction. TMB was catalyzed by HRP to produce a blue color product that changed into yellow after adding stop solution. The density of yellow is proportional to the ProGRP amount of sample captured in plate. Read the O.D. absorbance at 450nm in a microplate reader, and then the concentration of ProGRP can be calculated.

Background: Progastrin-releasing peptide (proGRP) is a recently identified biomarker of small cell lung cancer (SCLC). Plasma proGRP level could be a useful monitoring biomarker for patients with SCLC and the initial level may help with SCLC tumor staging. ProGRP was highly expressed in NCI-H446 cells and xenograft tissue. It could be used as a marker for quality control in sample processing and storage in biobanks. Korse CM1 et al study concluded that a high-risk proGRP level (more than twice the upper reference value) in patients with well-differentiated neuroendocrine tumours, WDNETs is a strong indication for a primary tumour in the lung. Besides CgA, proGRP is a complementary tumour marker for prognosis and treatment monitoring in patients with neuroendocrine tumour.

Oh HJ, Park HY, Kim KH, Park CK, Shin HJ, Lim JH, Kwon YS, Oh IJ, Kim YI, Lim SC, Kim YC, Kim SH, Shin MG. Progastrin-releasing peptide as a diagnostic and therapeutic biomarker of small cell lung cancer. J Thorac Dis. 2016 Sep;8(9):2530-2537. Hong Z, Shi Y, Liu Z, Zhou X, Yang Y, Tang J. Preliminary radioimmunoimaging and biodistribution of iodine-labeled single-chain antibody fragment against progastrin-releasing peptide (31-98) in small cell lung cancer xenografts. Chin Med J (Engl). 2014;127(11):2007-11. Kim SY, Kim JS, Hwang SH, Park HK, Lee JH, Lee DH, Hah SS, Park do Y. Progastrin-releasing peptide is a candidate marker for quality control in clinical sample processing and storage. Am J Clin Pathol. 2012 Feb;137(2):277-82. Korse CM1, Taal BG, Bonfrer JM, Vincent A, van Velthuysen ML, Baas P. An elevated progastrin-releasing peptide level in patients with well-differentiated neuroendocrine tumours indicates a primary tumour in the lung and predicts a shorter survival. Ann Oncol. 2011 Dec;22(12):2625-30.

Small volumes of ProGRP elisa kit vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS355781 is a ready-to-use microwell, strip-or-full plate ELISA (enzyme-linked immunosorbent assay) Kit for analyzing the presence of the Pro-Gastrin-releasing peptide, ProGRP, ELISA Kit target analytes in biological samples. The concentration gradients of the kit standards or positive controls render a theoretical kit detection range in biological research samples containing ProGRP. The ELISA analytical biochemical technique of the MBS355781 kit is based on ProGRP antibody-ProGRP antigen interactions (immunosorbency) and an HRP colorimetric detection system to detect ProGRP antigen targets in samples. The ELISA Kit is designed to detect native, not recombinant, ProGRP. Appropriate sample types may include undiluted body fluids and/or tissue homogenates, secretions. Quality control assays assessing reproducibility identified the intra-assay CV (%) and inter-assay CV(%).